FXYD4

Across TCGA pan-cancer cohorts, FXYD4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FXYD4 data layer compared with 16 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher FXYD4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FXYD4 expression acts as an unfavorable survival marker.

READ, LIHC, and UCEC are the cancer types where FXYD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.255	0.844	.004	21	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FXYD4–READ (DFS)

Open the READ breakdown →